(주)셀렉스라이프사이언스

R & D

ILIAS is the Leader of Next-Generation Exosome Therapeutics.

Pipeline

Inflammatory Disease

  • Sepsis : Exo-Target® loaded with anti-inflammatory protein which is delivered intra-cellularly into target cells (i.e. innate immune cells) to specifically inhibit sepsis causing inflammatory signaling pathway.
  • Preterm Birth : Exo-Target® can deliver anti-inflammatory protein through placenta barrier to control pre-term inflammation in the placenta which is the main cause of preterm labor of pregnant woman.

Inborn Errors of Metabolism

  • Gaucher’s Disease : In the metabolic disease, Exo-Target® can deliver the enzyme to the target cells in the liver and spleen for Type 1 Gaucher’s Disease (GD1) treatment. Exo-Target® can also across BBB for API delivery to the neuronal cells for Type 2 & 3 Gaucher’s Disease (GD2 and 3) treatment.

Pipeline Expandability

Our therapeutic exosomes, Exo-Target®, have high potential to be applied for
infinite pipelines depending on cargo proteins and targeting mechanisms.

Pipeline

Publication

TOP

개인정보취급방침

닫기

이메일주소무단수집거부

닫기

사이트맵

사이트맵

몬트리올의정서
국내이행법령
사업안내
특정물질 수출입
알림·자료실
민원서비스
닫기